Stocks / NASDAQ / Nuvalent Inc.

Nuvalent Inc.

Our Opinion

Nuvalent Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

We have, for example, observed preclinical CNS activity of NVL-520 and NVL-655 in studies with rats and mice. These studies may or may not be predictive of CNS penetrance and activity of NVL-520 or NVL-655 in human trials. (Page 22) Read the full document

Company Description

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Company Website: